Nephron SC's sterile drug manufacturing had unresolved cross-contamination and microbial contamination, making its drugs adulterated.
What happened
FDA inspected Nephron SC's West Columbia, SC drug manufacturing facility from March 28 to April 20, 2022. FDA found inadequate and untimely investigations of cross-contamination—including Bupivacaine found in other drug lots—and process-simulation (media fill) failures with Pseudomonas aeruginosa in blow-fill-seal cooling water, plus deficient environmental monitoring. The firm also failed to submit a required Field Alert Report within three working days; it later submitted FARs and recalled Ketorolac lot 023011 and four outsourcing products.
What FDA found
The firm failed to thoroughly investigate unexplained discrepancies or batch failures, including cross-contamination and microbial contamination.
21 CFR 211.192The firm failed to establish and follow written procedures to prevent microbiological contamination and validate aseptic and sterilization processes.
21 CFR 211.113(b)The firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.
21 CFR 211.42(c)(10)(iv)The firm failed to submit a Field Alert Report to FDA within three working days after learning of significant drug product changes or deterioration.
section 505(k) of the FD&C Act, 21 U.S.C. 355(k); 21 CFR 314.81(b)(1)(ii)
What FDA wants
FDA asks the company to provide comprehensive independent assessments and remediation plans for investigations/CAPA, cleaning validation, container closure and BFS equipment, and environmental monitoring, plus specific CAPA for the contamination. The excerpt does not state a response deadline.
Who should pay attention
- hospitals and clinics using Nephron sterile injectables
- compounding pharmacies and outsourcing facilities sharing equipment or facilities
- companies buying sterile drug products from contract manufacturers with mixed 503B and CGMP operations
This is a summary. Read the original letter on fda.gov.